Cargando…

The value of serum IL-4 to predict the survival of MDS patients

BACKGROUND: Immune indicators are routinely used for the detection of myelodysplastic syndrome (MDS), but these are not utilized as a reference indicator to assess prognosis in MDS-related prognostic evaluation systems, such as the World Health Organizational prognostic scoring system, the internati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhaoyun, Xu, Xintong, Zheng, Likun, Ding, Kai, Yang, Chun, Huang, Jincheng, Fu, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811803/ https://www.ncbi.nlm.nih.gov/pubmed/36600245 http://dx.doi.org/10.1186/s40001-022-00948-w

Ejemplares similares

Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/β-Catenin Pathway
por: Huang, Lei, et al.
Publicado: (2020)

P710: MONOCYTES MEDIATE NK CELL FUNCTION EXHAUSTION IN MDS PATIENTS VIA CD200/CD200R PATHWAY
por: Guo, Yixuan, et al.
Publicado: (2023)

The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
por: Zheng, Likun, et al.
Publicado: (2022)

Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients
por: Zhaoyun, Liu, et al.
Publicado: (2021)

P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
por: Morita, Yasuyoshi, et al.
Publicado: (2022)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

PB2136: THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Therapeutic strategies to enhance immune response induced by multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

PB2016: HIGH SERUM FERRITIN LEVELS AT DIAGNOSIS PREDICT WORSE PROGNOSIS IN ADVANCED MDS IN CHILDREN.
por: Liu, Chenmeng, et al.
Publicado: (2023)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Software needs for MDs
por: Ruggiero, F
Publicado: (1993)

LHC MDS For 2018
por: Tomás, R, et al.
Publicado: (2019)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

Activation of distinct inflammatory pathways in subgroups of LR-MDS
por: Schneider, Marie, et al.
Publicado: (2023)

Downregulation of MMP1 in MDS-derived mesenchymal stromal cells reduces the capacity to restrict MDS cell proliferation
por: Zhao, Sida, et al.
Publicado: (2017)

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
por: Huang, Feiteng, et al.
Publicado: (2020)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis
por: Yang, Yuan, et al.
Publicado: (2019)

PS Beams for SPS MDs
por: Manglunki, Django
Publicado: (1998)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

William Jarvie, M.D.S.
Publicado: (1922)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Predictive value of serum VEGF, IL-1 and TNF-α in the treatment of thromboangiitis obliterans by revascularization
por: Li, Zheng-Fei, et al.
Publicado: (2020)

TET2 deficiency promotes MDS-associated leukemogenesis
por: Huang, Feiteng, et al.
Publicado: (2022)

Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy
por: Liu, Zhaoyun, et al.
Publicado: (2022)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Results of MD’s in Autumn 1988 on e+
por: Canard, B, et al.
Publicado: (1989)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Targeting the Microenvironment in MDS: The Final Frontier
por: Teodorescu, Patric, et al.
Publicado: (2020)

High-risk MDS after HMAs
por: Adès, Lionel
Publicado: (2019)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

The Coming of Age of Preclinical Models of MDS
por: Liu, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aqnl2a6ldcqrh8nn1r2tvk260r